LMFP
AZN icon

Larry Mathis Financial Planning’s AstraZeneca AZN Stock Holding History

Larry Mathis Financial Planning’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,885
Closed -$530K – 159
2025
Q4 		$530K Buy
+2,885
New +$506K 0.47% 61

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $148B AUM

Larry Mathis Financial Planning's AZN Position: Q1 2026 in Review

Larry Mathis Financial Planning sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 2,885 shares — an estimated $530K sold.

Larry Mathis Financial Planning first reported a position in AZN in Q4 2025 and held it in 1 quarter. The position peaked at $530K in Q4 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Larry Mathis Financial Planning reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Larry Mathis Financial Planning sold 2,885 AstraZeneca shares in Q1 2026, an estimated $530K.
  • Larry Mathis Financial Planning first reported a position in AstraZeneca in Q4 2025 and held it in 1 quarter.
  • Larry Mathis Financial Planning's AstraZeneca position peaked at $530K in Q4 2025.
  • 1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Larry Mathis Financial Planning's 13F filing for Q1 2026, filed 22 Apr 2026.